Inviting an author to review:
Find an author and click ‘Invite to review selected article’ near their name.
Search for authorsSearch for similar articles
2
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Loss of Y in leukocytes as a risk factor for critical COVID-19 in men

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          The COVID-19 pandemic, which has a prominent social and economic impact worldwide, shows a largely unexplained male bias for the severity and mortality of the disease. Loss of chromosome Y (LOY) is a risk factor candidate in COVID-19 due to its prior association with many chronic age-related diseases, and its impact on immune gene transcription.

          Methods

          Publicly available scRNA-seq data of PBMC samples derived from male patients critically ill with COVID-19 were reanalyzed, and LOY status was added to the annotated cells. We further studied LOY in whole blood for 211 COVID-19 patients treated at intensive care units (ICU) from the first and second waves of the pandemic. Of these, 139 patients were subject to cell sorting for LOY analysis in granulocytes, low-density neutrophils (LDNs), monocytes, and PBMCs.

          Results

          Reanalysis of available scRNA-seq data revealed LDNs and monocytes as the cell types most affected by LOY. Subsequently, DNA analysis indicated that 46%, 32%, and 29% of critically ill patients showed LOY above 5% cut-off in LDNs, granulocytes, and monocytes, respectively. Hence, the myeloid lineage that is crucial for the development of severe COVID-19 phenotype is affected by LOY. Moreover, LOY correlated with increasing WHO score (median difference 1.59%, 95% HDI 0.46% to 2.71%, p=0.025), death during ICU treatment (median difference 1.46%, 95% HDI 0.47% to 2.43%, p=0.0036), and history of vessel disease (median difference 2.16%, 95% HDI 0.74% to 3.7%, p=0.004), among other variables. In 16 recovered patients, sampled during ICU stay and 93–143 days later, LOY decreased significantly in whole blood and PBMCs. Furthermore, the number of LDNs at the recovery stage decreased dramatically (median difference 76.4 per 10,000 cell sorting events, 95% HDI 55.5 to 104, p=6e−11).

          Conclusions

          We present a link between LOY and an acute, life-threatening infectious disease. Furthermore, this study highlights LOY as the most prominent clonal mutation affecting the myeloid cell lineage during emergency myelopoiesis. The correlation between LOY level and COVID-19 severity might suggest that this mutation affects the functions of monocytes and neutrophils, which could have consequences for male innate immunity.

          Supplementary Information

          The online version contains supplementary material available at 10.1186/s13073-022-01144-5.

          Related collections

          Most cited references50

          • Record: found
          • Abstract: found
          • Article: not found

          A Novel Coronavirus from Patients with Pneumonia in China, 2019

          Summary In December 2019, a cluster of patients with pneumonia of unknown cause was linked to a seafood wholesale market in Wuhan, China. A previously unknown betacoronavirus was discovered through the use of unbiased sequencing in samples from patients with pneumonia. Human airway epithelial cells were used to isolate a novel coronavirus, named 2019-nCoV, which formed a clade within the subgenus sarbecovirus, Orthocoronavirinae subfamily. Different from both MERS-CoV and SARS-CoV, 2019-nCoV is the seventh member of the family of coronaviruses that infect humans. Enhanced surveillance and further investigation are ongoing. (Funded by the National Key Research and Development Program of China and the National Major Project for Control and Prevention of Infectious Disease in China.)
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Characteristics of SARS-CoV-2 and COVID-19

            Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible and pathogenic coronavirus that emerged in late 2019 and has caused a pandemic of acute respiratory disease, named ‘coronavirus disease 2019’ (COVID-19), which threatens human health and public safety. In this Review, we describe the basic virology of SARS-CoV-2, including genomic characteristics and receptor use, highlighting its key difference from previously known coronaviruses. We summarize current knowledge of clinical, epidemiological and pathological features of COVID-19, as well as recent progress in animal models and antiviral treatment approaches for SARS-CoV-2 infection. We also discuss the potential wildlife hosts and zoonotic origin of this emerging virus in detail.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              brms: An R Package for Bayesian Multilevel Models Using Stan

                Bookmark

                Author and article information

                Contributors
                bozena.bruhn-olszewska@igp.uu.se
                jan.dumanski@igp.uu.se
                Journal
                Genome Med
                Genome Med
                Genome Medicine
                BioMed Central (London )
                1756-994X
                14 December 2022
                14 December 2022
                2022
                : 14
                : 139
                Affiliations
                [1 ]GRID grid.8993.b, ISNI 0000 0004 1936 9457, Department of Immunology, Genetics and Pathology and Science for Life Laboratory, , Uppsala University, ; Uppsala, Sweden
                [2 ]GRID grid.11451.30, ISNI 0000 0001 0531 3426, 3P-Medicine Laboratory, , Medical University of Gdańsk, ; Dębinki 7, 80-211 Gdańsk, Poland
                [3 ]GRID grid.10548.38, ISNI 0000 0004 1936 9377, National Bioinformatics Infrastructure Sweden, Department of Biochemistry and Biophysics, , Stockholm University, Science for Life Laboratory, ; Stockholm, Sweden
                [4 ]GRID grid.11451.30, ISNI 0000 0001 0531 3426, Department and Clinic of Rheumatology, Clinical Immunology, Geriatrics and Internal Medicine, , Medical University of Gdańsk, ; Gdańsk, Poland
                [5 ]GRID grid.8761.8, ISNI 0000 0000 9919 9582, Department of Laboratory Medicine, , Institute of Biomedicine and Biobank Core Facility, Sahlgrenska Academy at the University of Gothenburg, ; Gothenburg, Sweden
                [6 ]GRID grid.8761.8, ISNI 0000 0000 9919 9582, Department of Infectious Diseases, , Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, ; Gothenburg, Sweden
                [7 ]GRID grid.1649.a, ISNI 000000009445082X, Department of Infectious Diseases, Region Västra Götaland, , Sahlgrenska University Hospital, ; Gothenburg, Sweden
                [8 ]GRID grid.8993.b, ISNI 0000 0004 1936 9457, Zoonosis Science Center, Department of Medical Sciences, Uppsala, Sweden, , Uppsala University, ; Uppsala, Sweden
                [9 ]GRID grid.8993.b, ISNI 0000 0004 1936 9457, Department of Medical Sciences, Endocrine Oncology Unit, Uppsala University, ; Uppsala, Sweden
                [10 ]GRID grid.8993.b, ISNI 0000 0004 1936 9457, Department of Surgical Sciences, Anesthesiology and Intensive Care, , Uppsala University, ; Uppsala, Sweden
                [11 ]GRID grid.8993.b, ISNI 0000 0004 1936 9457, Hedenstierna laboratory, Department of Surgical Sciences, , Uppsala University, ; Uppsala, Sweden
                [12 ]GRID grid.8993.b, ISNI 0000 0004 1936 9457, Integrative Physiology, Department of Medical Cell Biology, , Uppsala University, ; Uppsala, Sweden
                Author information
                http://orcid.org/0000-0003-2141-0247
                http://orcid.org/0000-0002-6289-3815
                http://orcid.org/0000-0002-2451-4386
                http://orcid.org/0000-0001-8393-5845
                http://orcid.org/0000-0001-8050-2489
                http://orcid.org/0000-0001-5475-8448
                http://orcid.org/0000-0003-1644-2957
                http://orcid.org/0000-0002-5481-9148
                http://orcid.org/0000-0002-2788-5254
                http://orcid.org/0000-0002-6849-6220
                http://orcid.org/0000-0003-1257-4047
                http://orcid.org/0000-0002-0504-6492
                http://orcid.org/0000-0002-9203-5969
                http://orcid.org/0000-0002-7075-1059
                http://orcid.org/0000-0002-9673-2649
                http://orcid.org/0000-0002-1649-4880
                http://orcid.org/0000-0002-1976-4129
                http://orcid.org/0000-0002-2357-1020
                http://orcid.org/0000-0003-4675-1099
                http://orcid.org/0000-0003-2278-7951
                http://orcid.org/0000-0002-1489-1452
                Article
                1144
                10.1186/s13073-022-01144-5
                9747543
                36514076
                629bdc76-2b58-4941-97cc-7d0fcbbcd6b9
                © The Author(s) 2022

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                : 5 October 2022
                : 23 November 2022
                Funding
                Funded by: Uppsala University
                Categories
                Research
                Custom metadata
                © The Author(s) 2022

                Molecular medicine
                Molecular medicine

                Comments

                Comment on this article